ALSO NOTED: Nucryst drug fails trial; Dr. Bugg to retire from Biocryst; Pozen shares jump; and much more...

> Nucryst Pharmaceuticals announced that a mid-stage trial of its topical cream for dermatitis did not achieve its goal, according to a preliminary review of the data. The company plans to continue to study other uses of the drug. Report

> Chutes & Ladders: BioCryst Pharmaceuticals announced that Charles E. Bugg, Ph.D., the company's chairman, CEO and co-founder, has informed the board that he intends to retire in 2007. Dr. Bugg will retain his current duties as CEO until a replacement has taken office. Release

> Shares of Pozen jumped after the company announced it had received a previously announced up-front payment for a collaboration deal with AstraZeneca. Report

> Swiss authorities have approved Novartis' Sebivo for chronic hepatitis B. Report

> The makers of the Ortho Evra patch are adding a new warning about non-fatal blood clots associated with the patch. Report

And Finally... A massive new study of top research centers is dominated by U.S. universities. Article

Suggested Articles

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.